Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethnicity and Food Effect on PK of Lazertinib in Healthy Volunteers
NCT03556436Phase 1Completed
- Sponsor
- Yuhan
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yuhan. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration and Maximum Plasma Concentration. Started Jul 2018; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03556436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556436.